In clinical practice, this would theoretically mean that if a newly discovered tumor expresses CXCR4, [68Ga]Ga-Pentixafor PET could be complementary to tumor imaging, and facilitating surgical and radiotherapy planning. Here, CXCR4 is linked to neoplasm.